Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE June 20, 2017

Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) | Read more 


PRESS RELEASE June 19, 2017

Immune Receives NASDAQ Compliance Letter | Read more 


PRESS RELEASE June 15, 2017

Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events